BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26718792)

  • 1. Efficacy of Silexan in mixed anxiety-depression--A randomized, placebo-controlled trial.
    Kasper S; Volz HP; Dienel A; Schläfke S
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):331-340. PubMed ID: 26718792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
    Kasper S; Gastpar M; Müller WE; Volz HP; Möller HJ; Schläfke S; Dienel A
    Int J Neuropsychopharmacol; 2014 Jun; 17(6):859-69. PubMed ID: 24456909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial.
    Kasper S; Gastpar M; Müller WE; Volz HP; Möller HJ; Dienel A; Schläfke S
    Int Clin Psychopharmacol; 2010 Sep; 25(5):277-87. PubMed ID: 20512042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep--A randomized, placebo-controlled trial.
    Kasper S; Anghelescu I; Dienel A
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1960-7. PubMed ID: 26293583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review.
    Kasper S
    Int J Psychiatry Clin Pract; 2013 Nov; 17 Suppl 1():15-22. PubMed ID: 23808618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.
    Woelk H; Schläfke S
    Phytomedicine; 2010 Feb; 17(2):94-9. PubMed ID: 19962288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.
    Bartova L; Dold M; Volz HP; Seifritz E; Möller HJ; Kasper S
    Eur Arch Psychiatry Clin Neurosci; 2023 Feb; 273(1):51-63. PubMed ID: 35262795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials.
    Möller HJ; Volz HP; Dienel A; Schläfke S; Kasper S
    Eur Arch Psychiatry Clin Neurosci; 2019 Mar; 269(2):183-193. PubMed ID: 29150713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.
    Kasper S; Gastpar M; Müller WE; Volz HP; Möller HJ; Dienel A; Schläfke S
    Wien Med Wochenschr; 2010 Dec; 160(21-22):547-56. PubMed ID: 21170695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set.
    Kasper S; Möller HJ; Volz HP; Schläfke S; Dienel A
    Int Clin Psychopharmacol; 2017 Jul; 32(4):195-204. PubMed ID: 28379882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials.
    Dold M; Bartova L; Volz HP; Seifritz E; Möller HJ; Schläfke S; Kasper S
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1615-1628. PubMed ID: 36717399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder.
    Uehleke B; Schaper S; Dienel A; Schlaefke S; Stange R
    Phytomedicine; 2012 Jun; 19(8-9):665-71. PubMed ID: 22475718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological basis of the anxiolytic and antidepressant properties of Silexan®, an essential oil from the flowers of lavender.
    Müller WE; Sillani G; Schuwald A; Friedland K
    Neurochem Int; 2021 Feb; 143():104899. PubMed ID: 33181239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silexan in anxiety disorders: Clinical data and pharmacological background.
    Kasper S; Müller WE; Volz HP; Möller HJ; Koch E; Dienel A
    World J Biol Psychiatry; 2018 Sep; 19(6):412-420. PubMed ID: 28511598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of Silexan on sleep are mediated by its anxiolytic effect.
    Seifritz E; Schläfke S; Holsboer-Trachsler E
    J Psychiatr Res; 2019 Aug; 115():69-74. PubMed ID: 31121394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis.
    von Känel R; Kasper S; Bondolfi G; Holsboer-Trachsler E; Hättenschwiler J; Hatzinger M; Imboden C; Heitlinger E; Seifritz E
    Brain Behav; 2021 Apr; 11(4):e01997. PubMed ID: 33638614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging.
    Baldinger P; Höflich AS; Mitterhauser M; Hahn A; Rami-Mark C; Spies M; Wadsak W; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2014 Oct; 18(4):. PubMed ID: 25522403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
    Rickels K; Mathew S; Banov MD; Zimbroff DL; Oshana S; Parsons EC; Donahue SR; Kauffman M; Iyer GR; Reinhard JF
    J Clin Psychopharmacol; 2008 Apr; 28(2):235-9. PubMed ID: 18344738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.